Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vericiguat

FDA-approved product (tablet, oral), marketed as Verquvo.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vericiguat
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cardiovascular disease
  • Heart failure

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other vasodilators used in cardiac diseases
FDA pharmacologic class
Soluble Guanylate Cyclase Stimulator FDA label ↗
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA57.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.7% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae22.6% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis60.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vericiguat in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-8.8 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-8.7 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-8.5 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-8.9 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vericiguat with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • VITAL-IMPACT: Improving Cardiometabolic Health in Black Individuals Through Therapeutic Augmentation of Cyclic Guanosine Mono-Phosphate Signaling Pathway

    NCT06320951 · start 2026-12-01

    Registered record
    Registry ID
    NCT06320951
    Conditions
    Cardiovascular Diseases; Insulin Sensitivity/Resistance; Metabolic Disease; Metabolism; Energy Expenditure; Obesity
    Interventions
    Vericiguat 10 MG; Placebo; Insulin Sensitivity Test; Resting Energy and Exercise Energy Expenditure Assessment; White Adipose Tissue Biopsy; MRI-PET Scan for Brown Adipose Tissue Volume Assessment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-12-01
    Completion
    2029-04-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardiovascular Diseases; Insulin Sensitivity/Resistance; Metabolic Disease; Metabolism +2 more
    InterventionVericiguat 10 MG; Placebo; Insulin Sensitivity Test; Resting Energy and Exercise Energy Expenditure Assessment +2 more
    PhasePhase 2
    Registry statusNot yet recruiting

  • Vericiguat for the Inhibition of Calcific Aortic Valve Stenosis Progression

    NCT07715279 · start 2026-08-20

    Registered record
    Registry ID
    NCT07715279
    Conditions
    Calcific Aortic Valve Disease; AORTIC VALVE DISEASES; Aortic Valve Stenosis
    Interventions
    Vericiguat (BAY1021189); Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Not yet recruiting
    Start
    2026-08-20
    Completion
    2029-11-30
    Enrolment
    238

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCalcific Aortic Valve Disease; AORTIC VALVE DISEASES; Aortic Valve Stenosis
    InterventionVericiguat (BAY1021189); Placebo
    PhasePhase 2
    Registry statusNot yet recruiting

  • Micro-axial Flow Pump-Supported PCI in Complex Coronary Artery Disease With Ischemic LV Dysfunction

    NCT07678021 · start 2026-08-01

    Registered record
    Registry ID
    NCT07678021
    Conditions
    Coronary Artery Disease (CAD)
    Interventions
    Microaxial pump-supported PCI; Optimal medical therapy (OMT)
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-08-01
    Completion
    2029-12-31
    Enrolment
    452

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCoronary Artery Disease (CAD)
    InterventionMicroaxial pump-supported PCI; Optimal medical therapy (OMT)
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Comparing the Efficacy and Safety of Vericiguat With Standard Medical Treatment in Heart Failure Patients

    NCT07697833 · start 2026-07-15

    Registered record
    Registry ID
    NCT07697833
    Conditions
    Heart Failure With Reduced Ejection Fraction (HFrEF)
    Interventions
    Vericiguat tablet; Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-07-15
    Completion
    2027-07-31
    Enrolment
    500

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Reduced Ejection Fraction (HFrEF)
    InterventionVericiguat tablet; Placebo
    PhasePhase 4
    Registry statusNot yet recruiting

  • Efficacy of Verciguat in TR and RV Failure

    NCT07668739 · start 2026-07-01

    Registered record
    Registry ID
    NCT07668739
    Conditions
    HFrEF; Tricuspid Regurgitation (TR)
    Interventions
    Vericiguat
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-07-01
    Completion
    2028-05-31
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHFrEF; Tricuspid Regurgitation (TR)
    InterventionVericiguat
    PhasePhase 4
    Registry statusNot yet recruiting

  • Perioperative Vericiguat in Patients Undergoing Cardiovascular Surgery

    NCT07594509 · start 2026-05-31

    Registered record
    Registry ID
    NCT07594509
    Conditions
    Cardio Vascular Disease; Cardiopulmonary Bypass
    Interventions
    Vericiguat; Standard of Care Group
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-05-31
    Completion
    2030-12-31
    Enrolment
    600

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCardio Vascular Disease; Cardiopulmonary Bypass
    InterventionVericiguat; Standard of Care Group
    PhaseNot applicable
    Registry statusNot yet recruiting

  • Vericiguat in Decompensated Cardiac Failure: Clinical Insights on Addition to Guidelines Derived Medical Therapy-VERCIG Trial

    NCT07444398 · start 2026-01-01

    Registered record
    Registry ID
    NCT07444398
    Conditions
    Decompensated Heart Failure
    Interventions
    Vericiguat tablet; Sacubitril / Valsartan
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-01-01
    Completion
    2026-03-31
    Enrolment
    130

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionDecompensated Heart Failure
    InterventionVericiguat tablet; Sacubitril / Valsartan
    PhasePhase 1
    Registry statusRecruiting

  • A Clinical Study Using FAPI-PET Imaging to Assess the Postoperative Effects of TAVI in Patients With Aortic Stenosis

    NCT07335900 · start 2025-12-19

    Registered record
    Registry ID
    NCT07335900
    Conditions
    Severe Aortic Valve Stenosis
    Interventions
    Transcatheter Aortic Valve Implantation; Optimal medication treatment
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-12-19
    Completion
    2027-05-30
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionSevere Aortic Valve Stenosis
    InterventionTranscatheter Aortic Valve Implantation; Optimal medication treatment
    PhaseNot applicable
    Registry statusRecruiting

  • Vericiguat and Reverse Remodeling Indices in Heart Failure

    NCT07405944 · start 2025-11-01

    Registered record
    Registry ID
    NCT07405944
    Conditions
    Heart Failure With Reduced Ejection Fraction (HFrEF); Chronic Heart Failure
    Interventions
    Vericiguat; Guideline Directed Medical Therapy for Heart Failure (GDMT)
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-11-01
    Completion
    2027-12-31
    Enrolment
    60

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure With Reduced Ejection Fraction (HFrEF); Chronic Heart Failure
    InterventionVericiguat; Guideline Directed Medical Therapy for Heart Failure (GDMT)
    PhasePhase 4
    Registry statusRecruiting

  • An Observational Study to Learn More About How Safe Vericiguat is and How Well it Works in Indian People With Chronic Heart Failure With Reduced Ejection Fraction and Worsening Chronic Heart Failure Under Real World Conditions

    NCT06632483 · start 2025-09-08

    Registered record
    Registry ID
    NCT06632483
    Conditions
    Chronic Heart Failure With Reduced Ejection Fraction; Worsening Chronic Heart Failure
    Interventions
    Vericiguat (Verquvo, BAY1021189)
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Active not recruiting
    Start
    2025-09-08
    Completion
    2026-06-30
    Enrolment
    604

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Heart Failure With Reduced Ejection Fraction; Worsening Chronic Heart Failure
    InterventionVericiguat (Verquvo, BAY1021189)
    PhaseNot recorded
    Registry statusActive not recruiting

  • COgnitioN With VERiciGuat Evaluation in Heart Failure

    NCT06601465 · start 2025-06-03

    Registered record
    Registry ID
    NCT06601465
    Conditions
    Heart Failure; Cognitive Impairment
    Interventions
    Vericiguat
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-06-03
    Completion
    2028-07-16
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Cognitive Impairment
    InterventionVericiguat
    PhasePhase 2
    Registry statusRecruiting

  • A Study of Real-world Events of Vericiguat in Patients With Chronic Kidney Disease and Heart Failure

    NCT07047547 · start 2025-06-01

    Registered record
    Registry ID
    NCT07047547
    Conditions
    Hemodialysis Complication; Heart Failure
    Interventions
    Vericiguat
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-06-01
    Completion
    2026-06-01
    Enrolment
    118

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHemodialysis Complication; Heart Failure
    InterventionVericiguat
    PhaseNot applicable
    Registry statusRecruiting

  • Efficacy and Safety of Early Initiation of Vericiguat in Heart Failure After Acute Myocardial Infarction

    NCT06812546 · start 2025-04-01

    Registered record
    Registry ID
    NCT06812546
    Conditions
    Heart Failure; Acute Myocardial Infarction (AMI); Acute Heart Failure (AHF)
    Interventions
    Vericiguat
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2025-04-01
    Completion
    2026-12-30
    Enrolment
    200

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHeart Failure; Acute Myocardial Infarction (AMI); Acute Heart Failure (AHF)
    InterventionVericiguat
    PhasePhase 4
    Registry statusNot yet recruiting

  • The Impact of Vericiguat on Microvascular Function in Patients With Documented Vasospastic Angina Pectoris

    NCT06415227 · start 2025-02-10

    Registered record
    Registry ID
    NCT06415227
    Conditions
    Vasospastic Angina
    Interventions
    Vericiguat
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2025-02-10
    Completion
    2026-07-13
    Enrolment
    57

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionVasospastic Angina
    InterventionVericiguat
    PhasePhase 2
    Registry statusCompleted

  • Vericiguat for Heart Failure With Reduced Ejection Fraction After Myocardial Infarction

    NCT06717204 · start 2025-01-01

    Registered record
    Registry ID
    NCT06717204
    Conditions
    HFrEF - Heart Failure With Reduced Ejection Fraction; Myocardial Infarction (MI)
    Interventions
    Vericiguat Oral Tablet [Verquvo]; Prescription Drugs
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-01-01
    Completion
    2027-12-31
    Enrolment
    210

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHFrEF - Heart Failure With Reduced Ejection Fraction; Myocardial Infarction (MI)
    InterventionVericiguat Oral Tablet [Verquvo]; Prescription Drugs
    PhaseNot recorded
    Registry statusNot yet recruiting